D.A. Davidson & CO. Has $696,000 Stock Position in Moderna, Inc. (NASDAQ:MRNA)

D.A. Davidson & CO. decreased its position in Moderna, Inc. (NASDAQ:MRNA) by 58.1% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 16,727 shares of the company’s stock after selling 23,210 shares during the period. D.A. Davidson & CO.’s holdings in Moderna were worth $696,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the company. State Street Corp raised its holdings in Moderna by 12.1% in the 3rd quarter. State Street Corp now owns 16,847,212 shares of the company’s stock valued at $1,125,899,000 after acquiring an additional 1,823,276 shares in the last quarter. Geode Capital Management LLC raised its holdings in Moderna by 2.6% in the 3rd quarter. Geode Capital Management LLC now owns 7,069,580 shares of the company’s stock valued at $470,670,000 after acquiring an additional 178,115 shares in the last quarter. Wellington Management Group LLP raised its holdings in Moderna by 21.0% in the 3rd quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock valued at $349,166,000 after acquiring an additional 906,114 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Moderna by 0.5% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,890,812 shares of the company’s stock worth $260,023,000 after buying an additional 19,819 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its holdings in shares of Moderna by 6.2% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 3,073,934 shares of the company’s stock worth $205,431,000 after buying an additional 178,939 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on MRNA. UBS Group dropped their target price on Moderna from $96.00 to $78.00 and set a “buy” rating for the company in a report on Wednesday, February 19th. The Goldman Sachs Group cut Moderna from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $99.00 to $51.00 in a report on Wednesday, January 29th. Evercore ISI set a $50.00 target price on Moderna in a report on Friday, February 14th. Leerink Partners dropped their target price on Moderna from $31.00 to $27.00 and set an “underweight” rating for the company in a report on Thursday, January 16th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $69.00 price target (down from $115.00) on shares of Moderna in a report on Monday, November 18th. Four research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $60.63.

Insider Transactions at Moderna

In related news, insider Shannon Thyme Klinger sold 1,418 shares of the firm’s stock in a transaction on Friday, November 29th. The stock was sold at an average price of $42.79, for a total transaction of $60,676.22. Following the sale, the insider now owns 19,717 shares of the company’s stock, valued at approximately $843,690.43. This trade represents a 6.71 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders have sold 2,664 shares of company stock worth $115,210 in the last three months. Insiders own 15.20% of the company’s stock.

Moderna Stock Down 4.6 %

NASDAQ:MRNA opened at $33.90 on Tuesday. Moderna, Inc. has a 12-month low of $29.25 and a 12-month high of $170.47. The firm has a market capitalization of $13.05 billion, a P/E ratio of -3.65 and a beta of 1.59. The stock’s fifty day simple moving average is $37.89 and its 200-day simple moving average is $52.10.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.